MedTrace Logo

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05797948 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-04-04

No results posted yet for this study

Summary

This study intends to use Obinutuzumab, Zanubrutinib, and Lenalidomide sequential CD19/CD22 CAR-T in the treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma patients. The main purpose of this study is to explore a new treatment mode for R/R B-NHL patients and observe the efficacy and safety of this treatment regimen.

Conditions

  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

Obinutuzumab

Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；

DRUG

Zanubrutinib

Zanubrutinib 160mg (2 capsules) oral bid；

DRUG

Lenalidomide

Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.

DRUG

CD19/CD22 CAR-T

Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.

DRUG

Azacitidine For Injection

Azacitidine For Injection 100mg i.h. d1-d5;

DRUG

Fludarabine

Fludarabine 300mg/m2 ivgtt d3-d5;

DRUG

Cyclophosphamide

Cyclophosphamide 300mg/m2 ivgtt d3-d5.

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05797948 on ClinicalTrials.gov